

Effective synthesis of novel furan-fused pentacyclic triterpenoids via anionic 5-exo dig cyclization of 2-alkynyl-3-oxotriterpene acids

Rinat R. Gubaidullin, Darina S. Yarmukhametova,
Darya A. Nedopekina, Rezeda R. Khalitova, and Anna Yu. Spivak*

*Institute of Petrochemistry and Catalysis, Russian Academy of Sciences,
141 Prospekt Oktyabrya, Ufa 450 075, Russian Federation*

E-mail: spivak.ink@gmail.com


Received 04-20-2017

Accepted 06-28-2017

Published on line 07-23-2017

Abstract

An efficient synthetic route to biologically interesting furan-fused pentacyclic triterpenoids with a furan moiety 2,3-annulated to the terpenoid skeleton has been developed. New heterocyclic triterpenoids have been obtained in moderate to good yields by base-promoted 5-exo-dig cyclization of the pent-4-yn-1-one moiety in ring A of the 2-alkynyl-3-oxotriterpene acids of lupane, ursane and oleanane type.



Keywords: Pentacyclic triterpenoids, heterocycles, furans, 4-pentynones, 5-exo-dig cyclisation

Introduction



Pentacyclic triterpenoids, which are abundant in plants, are usually produced as secondary metabolites. These compounds are of interest for pharmacological investigations, as they exhibit a variety of biological activities, including anti-inflammatory, antiviral, hepatoprotective, antiparasitic, and, what is important, anticancer activities, which are successfully combined with low systemic toxicity for animals.¹⁻⁸ Owing to the presence of easily transformable functional groups (OH, COOH, C=C), pentacyclic triterpenoids possess a good synthetic potential and are actively used as promising structural platforms for the discovery of new drugs. Currently, in order to increase the biological potential and bioavailability of native triterpene acids, their numerous synthetic analogues have been prepared. Among them, considerable attention has been given to heterocyclic triterpenoids with various nitrogen, sulfur, and oxygen heterocycles.⁹⁻¹⁸ The biological activity of triterpenoid heterocycles are promising and many of them have been studied as antitumor,⁹⁻¹³ antiosteoporosis,^{14,15} anti-inflammatory¹⁶ and antileishmanial agents.^{17,18} Among this group of potentially biologically active compounds, furan triterpenoid derivatives have not been reported in the literature. Meanwhile, polysubstituted furans represent an important class of oxygen heterocycles and occur as structural moieties in many natural products and pharmaceutically important substances.¹⁹ Furans are used in medicinal chemistry as useful intermediates in the synthetic transformations aimed at the development of new pharmaceutical agents.²⁰ A recent trend in the synthesis of polysubstituted furans is related to the development of atom-economic methods for the design of the furan ring via intramolecular cyclization of acyclic alkynyl ketones or alcohols induced by strong bases²¹⁻²³ or transition metal-based catalysts.²⁴⁻²⁷ These rational methods that give furan heterocycles under mild conditions provide a good alternative to numerous classical methods for furan synthesis, in particular known cyclocondensations of carbonyl compounds (Paal–Knorr or Feist–Benary syntheses).

Recently we developed a chemoselective method for the synthesis of C(2)-propargyl-substituted lupane- and ursane-type triterpenoids based on α -alkylation with propargyl bromide of potassium enoxytriethylborates generated from 3-oxotriterpenes under the action of $\text{KN}(\text{SiMe}_3)_2\text{-Et}_3\text{B}$.²⁸

In this work, the C-2 alkynyl derivatives of 3-oxotriterpene acids were used as the key intermediates for the synthesis of new furanotriterpenoids by anionic 5-*exo*-dig cyclization of the pent-4-yn-1-one moiety in the A-ring of the pentacyclic skeleton. A specific feature of this transformation is that the pent-4-yn-1-one moiety is incorporated in polycyclic molecules, structurally related to steroids, whereas in many cases, acyclic alkynyl ketones have been used as the initial substrates for cyclization into furans.²¹⁻²⁷ To our knowledge, only one research group has described the synthesis of [3,2-*b*]furan-fused steroids through anionic annulation reaction of 4-pentynone moiety on the A-ring of a steroid core.²⁹

Results and Discussion

The initial compounds **8-10** were synthesized by a reported method²⁸ via the reaction of propargyl bromide with the enolate anion, which was formed by treating the methyl esters of betulonic **2**, ursonic **4**, and oleanonic acids **6** with $\text{KN}(\text{SiMe}_3)_2\text{-Et}_3\text{B}$ in 1,2-dimethoxyethane at room temperature. The reactions afforded C(2)-propargyl triterpene acid derivatives **8-10** with equatorial-oriented α -propynyl groups (Scheme 1).




Reagents and conditions: a, CrO₃, H₂SO₄, acetone, or PCC, CH₂Cl₂; b, CH₂N₂, Et₂O; c, KN(SiMe₃)₂-Et₃B, DME.

Scheme 1. The preparation of C-2 propargyl triterpene acid derivatives **8-10**.

The cyclization conditions were selected in relation to lupane triterpenoid **8**. Upon the reaction with superbases,³⁰ BuOK^t-DMSO, BuOK^t-DMF, BuOK^t-DME, KOH-THF, or KOH-DMSO, at room temperature over a period of 1–2 h, compound **8** was fully converted into a complex mixture of oligomeric compounds, in which the desired product **11a** was not found. The use of KN(SiMe₃)₂ in DMSO gave heterocycle **11a** in a yield not exceeding 36%. The expected compound **11a** was obtained in a reasonable yield of 58% by treatment of terpenoid **8** with KN(SiMe₃)₂ in dimethoxyethane at room temperature for 30 min. With longer reaction times, the yield of furan derivative **11a** was lower as a result of formation of oligomeric side products. Under the

optimized conditions, methyl ursonate **9** and methyl oleonate **10** were converted to heterocyclic compounds **12a** and **13a** in 56% and 54% yields, respectively (Scheme 2, Table 1).



Reagents and conditions: a, $\text{KN}(\text{SiMe}_3)_2\text{-Et}_3\text{B}$, DME, rt, Ar; b, Lil, DMF, reflux, Ar

Scheme 2. Synthesis of [3,2-*b*]furan fused triterpenoids **11a,b**, **12a,b** and **13a,b**.


Demethylation of the sterically hindered ester group in compounds **11a-13a** via halideolysis with Lil in DMF²⁸ afforded **11b-13b** in 54-56% yield (Scheme 2).

In order to broaden the applicability of this method, aryl groups with various substituents in the aromatic ring (4-Cl, 4-Br, 4-F, 3,4,5-(OMe)₃, 2-Me, 4-NO₂) were introduced into the terminal acetylenic moiety of compounds **8-10**. These products were obtained in excellent yield (80-85%) by the Sonogashira reaction in the presence of $\text{PdCl}_2(\text{PPh}_3)_2$, CuI and Et₃N (Scheme 3).

The resulting alkynyl triterpenoid derivatives **14a-g**, **17**, and **19** were successfully converted into triterpene furans **15a-g**, **18a** and **20a**. Cleavage of methyl esters afforded compounds **16a-f**, **18b** and **20b**. Triterpenoids with arylalkynyl substituents were more reactive in this intramolecular cyclization than the substrates containing a terminal acetylenic bond. As opposed to cyclization of triterpenoid **8**, compound **15a** was transformed into furan derivative **15a** in a good yield (54–73%) in the presence of various basic reagents: BuOK^t-DMSO, $\text{KN}(\text{SiMe}_3)_2\text{-DMSO}$, BuOK^t-DME or $\text{KN}(\text{SiMe}_3)_2\text{-DME}$. However the best yield of furan derivative **14a** (73%) was obtained with the $\text{KN}(\text{SiMe}_3)_2\text{-DME}$ (Table 1). Among the tested 2-arylacetylenic derivatives of betulonic acid **14a-g** only triterpenoid **14g** (R = 4-O₂NC₆H₄) was a problematic compound. Intramolecular cyclisation provided a 19% isolation yield of furanoterpenoid **15g** and led to the formation of large amounts of side-products.

Aryl-substituted acetylene derivatives **14a-g**, **17**, and **19** were cycloisomerized on treatment with $\text{KN}(\text{SiMe}_3)_2$ -DME markedly faster (in 10-12 min) than propargyl-substituted triterpenoids **8-10** (30 min) to give the target reaction products **15a-g**, **18a**, and **20a** in higher yields (70-77%).

Table 1. Reaction conditions for the synthesis of [3,2-*b*]furan-fused triterpenoids




Entry	C-2-alkynyl triterpenoids	R	Base	Solvent	[3,2- <i>b</i>]furan-fused triterpenoids	Yield ^a %
1	8	H	BuOK ^t	DMSO	11a	0
2	8	H	BuOK ^t	DMF	11a	0
3	8	H	BuOK ^t	DME	11a	0
4	8	H	KOH	THF	11a	0
5	8	H	KOH	DMSO	11a	0
6	8	H	$\text{KN}(\text{SiMe}_3)_2$	DMSO	11a	36
7	8	H	$\text{KN}(\text{SiMe}_3)_2$	DME	11a	58
8	9	H	$\text{KN}(\text{SiMe}_3)_2$	DME	12a	56
9	10	H	$\text{KN}(\text{SiMe}_3)_2$	DME	13a	54
10	14a	Ph	BuOK ^t	DMSO	15a	54
11	14a	Ph	BuOK ^t	DME	15a	70
12	14a	Ph	$\text{KN}(\text{SiMe}_3)_2$	DMSO	15a	57
13	14a	Ph	$\text{KN}(\text{SiMe}_3)_2$	DME	15a	73
14	14b	4-BrC ₆ H ₄	$\text{KN}(\text{SiMe}_3)_2$	DME	15b	71
15	14c	4-ClC ₆ H ₄	$\text{KN}(\text{SiMe}_3)_2$	DME	15c	70
16	14d	4-FC ₆ H ₄	$\text{KN}(\text{SiMe}_3)_2$	DME	15d	72
17	14e	2-CH ₃ C ₆ H ₄	$\text{KN}(\text{SiMe}_3)_2$	DME	15e	77
18	14f	3,4,5-(CH ₃ O) ₃ C ₆ H ₂	$\text{KN}(\text{SiMe}_3)_2$	DME	15f	73
19	14g	4-O ₂ NC ₆ H ₄	$\text{KN}(\text{SiMe}_3)_2$	DME	15g	19
20	17	Ph	$\text{KN}(\text{SiMe}_3)_2$	DME	18a	71
21	19	Ph	$\text{KN}(\text{SiMe}_3)_2$	DME	20a	72

^a Yield of isolated product.

The structures of all new compounds were confirmed by conventional analytical methods. The ¹H and ¹³C NMR spectra of furan-fused triterpenoids adequately reflected their structure. Indeed, the ¹³C NMR spectrum of compound **11a** exhibited no signals for the acetylene and carbonyl carbon atoms, indicating that these functional groups of the initial methyl betulonate **8** were transformed in the intramolecular cyclization. Apart from the characteristic signal for the quaternary C-20 carbon atom (150.57 ppm), the spectrum exhibited

three new signals for quaternary carbon atoms (DEPT, HSQC) at 113.68, 149.57, and 154.44 ppm, which were assigned to C-2, C-5', and C-3, respectively. The ^1H NMR spectrum contained, apart from the signals for protons at C-29, a new singlet for the vinylic H-4' proton at about 5.68 ppm. The proton signals for the methyl group at the furan C-5' atom occurred at 2.26 ppm. The (Me)C-5' carbon atom resonated at 13.71 ppm. The spectroscopic data indicated the presence of tetrasubstituted C-2–C-3 and trisubstituted C-4'–C-5' double bonds in compound **11a**.



Reagents and conditions: a, ArI, PdCl₂(PPh₃)₂, CuI, Et₃N, DMF, Ar, 20 °C; b, KN(SiMe₃)₂, DME, 20 °C or BuOK[†], DME, 20 °C. c, Lil, DMF, reflux, Ar.

Scheme 3. Synthesis of [3,2-*b*]furan fused triterpenoids **15a-g**, **16a-f**, **18a,b** and **20a,b**.

The base-promoted ring closure in acyclic alkynyl ketones and alcohols occurs via the addition of oxygen-based nucleophilic group to the carbon-carbon triple bond. Agreement with Baldwin rules for ring formation cyclization can proceed along two pathways (5-*exo*-dig or 6-*endo*-dig cyclization) to give either 2-alkylfurans or 4*H*-pyrans, respectively (Figure 1).^{31,32}




Figure 1. Assumed pathway to furan ring formation.

The $\text{KN}(\text{SiMe}_3)_2$ -promoted cyclization of compounds **8-10**, **14a-g**, **17**, and **19** proceeded with high regioselectivity as a 5-*exo*-dig cyclization according to the probable^{21,22} pathway shown in Figure 1. Apparently, elimination of the methine proton at the C-2 atom of ring A of triterpenoids **8-10**, **14a-g**, **17**, and **19** is followed by 5-*exo*-dig attack by the nucleophilic enolate oxygen on the triple bond of intermediate **A** to give intermediate **B**. The protodemetalation during hydrolysis of intermediate **B** affords an unstable alkylidene dihydrofuran intermediate **C**, which undergoes a rapid isomerization to furan-fused triterpenoid.

Conclusions

We have developed an efficient procedure to synthesize new furan-fused lupane-, ursane, and oleanane-type pentacyclic triterpenoids. The synthesis is based on $\text{KN}(\text{SiMe}_3)_2$ - or BuOK^t -promoted cycloisomerization of accessible 2-alkynyl-3-oxotriterpene acid derivatives in dimethoxyethane. Future research will address transition metal complex-catalyzed heterocyclization of acetylene derivatives of triterpene acids.

Experimental Section

General. IR spectra were recorded on a Specord IR-75 spectrometer (thin films or solutions in CHCl_3). ^1H and ^{13}C NMR spectra were recorded on a Bruker Avance-500 instrument (500.13 (^1H) and 125.78 MHz (^{13}C)) or on a Bruker Avance-400 instrument (400.13 (^1H) and 100.62 MHz (^{13}C)) in CDCl_3 with Me_4Si as the internal standard. Mass spectra of new compounds were recorded on a Bruker-Autoflex III spectrometer (MALDI TOF,

positive ion mode, sinapic acid as the matrices) or on an LCMS-2010 EV (Shimadzu) spectrometer of the UfIC RAS Center for Collective Use "Chemistry". The measurements were performed on the positive and negative ions. Solution of compounds in acetonitrile:H₂O (95:5) were injected, using a syringe the flow rate 0.1 ml min⁻¹. The carrier gas was nitrogen (2.0 L min⁻¹), the interface temperature was 250 °C. Optical rotation was determined on a Perkin–Elmer-141 polarimeter. Specific rotation $[\alpha]_D$ is expressed in (deg mL)/(g dm); the concentration of the solution *c* is expressed in g/100 mL. Elemental analysis was carried out on a Carlo Erba 1106 analyzer. TLC was carried out on Sorbfil plates (Sorbpolimer, Krasnodar, Russia) in hexane–EtOAc (from 30:1 to 1:1); spots were visualized with anisaldehyde. Silica gel L (KSKG grade, 50–160 μm) was employed for column chromatography. The starting compounds betulin, betulinic acid, ursolic acid and reagents: BEt₃ (95%), KN(SiMe₃)₂ (1 M solution in THF), propargyl bromide, Lil, CuI, PdCl₂(PPh₃)₂, aryl iodide (C₆H₅I, IC₆H₄Br, IC₆H₄Cl, IC₆H₄F, IC₆H₄NO₂, IC₆H₂(OCH₃)₃, IC₆H₄CH₃, Et₃N, DMF, DME (dimethoxyethane), (Aldrich). Betulonic and betulinic acids were obtained from betulin according to known procedures.³³

General procedure for the synthesis of [3,2-*b*]furano-fused triterpenoids 11a-13a

Starting triterpenoids **8-10** were prepared as previously reported.²⁸ A 1 M solution of KN(SiMe₃)₂ (0.51 mL, 0.51 mmol) in THF was added to a solution of triterpenoids **8-10** (0.39 mmol) in DME (6 mL). The reaction mixture was stirred at room temperature under an argon atmosphere. The completion of reaction was monitored by TLC analysis. After 30 min reaction mixture was neutralized with 5% HCl (aq). The product was extracted with EtOAc (3 × 10 mL). The combined extracts were dried with MgSO₄ and concentrated. The residue was purified by column chromatography on SiO₂ with hexane/EtOAc (30:1) as an eluent to give the appropriate compound **11a-13a**.

Methyl 5'-methylfurano[3,2-*b*]lup-20(29)-en-28-oate (11a). Colorless crystals (58%). mp 71-73 °C. $[\alpha]_D^{21} +29.7^\circ$ (*c* 0.53, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ_H 5.68 (s, 1H, H-4'), 4.78, 4.64 (both br s, 2H, H-29), 3.70 (s, 3H, OMe), 3.05 (m, 1H, H-19), 2.35 (d, 1H, *J* 15 Hz, H^a-1), 2.26 (s, 3H, Me-5'), 2.29-1.34 (m, 21H, CH, CH₂ in pentacyclic skeleton and 1H, H^b-1), 1.72 (s, 3H, H-30), 1.22, 1.11, 1.01, 0.99, 0.86 (all s, 3H each, H-23–H-27). ¹³C NMR (100 MHz, CDCl₃): δ_C 176.67, 154.45, 150.57, 149.58, 113.68, 109.62, 106.78, 56.60, 53.62, 51.27, 49.45, 49.22, 46.97, 42.41, 40.72, 38.64, 38.57, 38.40, 36.97, 34.60, 33.51, 32.15, 30.62, 29.79, 29.16, 25.63, 21.39, 21.39, 19.40, 18.98, 16.30, 15.70, 14.72, 13.72. Anal. Calcd for C₃₄H₅₀O₃: C, 80.58; H, 9.94. Found: C, 80.61; H, 9.91. MS (APCI): *m/z* [M+H]⁺, found 507. [C₃₄H₅₀O₃]⁺ requires 506.38.

Methyl 5'-methylfurano[3,2-*b*]urs-12-en-28-oate (12a). Colorless crystals (56%). mp 76-78 °C. $[\alpha]_D^{19} +80.7^\circ$ (*c* 0.60, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ_H 5.69 (s, 1H, H-4'), 5.33 (m, 1H, H-12), 3.64 (s, 3H, OMe), 2.33 (d, 1H, *J* 15 Hz, H^a-1), 2.28 (m, 1H, H-18), 2.26 (s, 3H, Me-5'), 2.05-1.03 (m, 19H, CH, CH₂ in pentacyclic skeleton and 1H, H^b-1), 1.23, 1.13, 1.12, 0.95, 0.82 (all s, 3H each, H-23–H-27), 0.96 (d, 3H, *J* 5Hz, H-30), 0.88 (d, 3H, *J* 5Hz, H-30). ¹³C NMR (125 MHz, CDCl₃): δ_C 178.10, 154.41, 149.64, 138.04, 125.73, 113.62, 106.65, 53.56, 53.04, 51.47, 49.11, 48.19, 42.14, 39.58, 39.14, 38.89, 38.37, 38.29, 36.66, 34.48, 32.42, 30.70, 29.36, 28.08, 24.29, 23.49, 23.36, 21.50, 21.18, 19.02, 17.04, 16.80, 15.67, 13.72. Anal. Calcd for C₃₄H₅₀O₃: C, 80.58; H, 9.94. Found: C, 80.47; H, 9.85. MS (APCI): *m/z* [M+H]⁺, found 507. [C₃₄H₅₀O₃]⁺ requires 506.38.

Methyl 5'-methylfurano[3,2-*b*]olean-12-en-28-oate (13a). Colorless crystals (54%). mp 80-82 °C. $[\alpha]_D^{21} +105.47^\circ$ (*c* 0.59, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ_H 5.69 (s, 1H, H-4'), 5.32 (m, 1H, H-12), 3.65 (s, 3H, OMe), 2.91 (m, 1H, H-18), 2.30 (d, 1H, *J* 15 Hz, H^a-1), 2.26 (s, 3H, Me-5'), 2.02-1.22 (m, 19H, CH, CH₂ in pentacyclic skeleton and 1H, H^b-1), 1.23, 1.17, 1.13, 0.94, 0.81 (all s, 3H each, H-23–H-27), 0.93 (d, 3H, *J* 5 Hz, H-30), 0.96 (d, 3H, *J* 5Hz, H-30). ¹³C NMR (100 MHz, CDCl₃): δ_C 178.31, 154.45, 149.63, 143.63, 122.52, 113.57, 106.66, 53.53, 51.54, 46.80, 46.19, 45.90, 41.80, 41.43, 39.38, 38.37, 38.11, 34.48, 33.90, 33.13, 32.39, 32.10, 30.71,

29.33, 27.77, 25.77, 23.63, 23.40, 23.14, 21.52, 19.05, 16.61, 15.50, 13.72. Anal. Calcd for C₃₄H₅₀O₃: C, 80.58; H, 9.80. Found: C, 80.49; H, 9.93. *m/z* [M+H]⁺, found 507. [C₃₄H₅₀O₃]⁺ requires 506.38.

General procedure for the synthesis of 2 α -arylpropynyl triterpenoids derivatives 14a-g, 17 and 19 via Sonogashira coupling reaction. An oven-dried flask equipped with a magnetic stirring was flushed with argon. Then to a mixture of corresponding triterpenoids (0.3 mmol) and an aryl iodide (0.25 mmol) were dissolved in DMF (4.5 mL), Et₃N (0.34 mL, 2.47 mmol) was added. Then CuI (4.6 mg, 0.03 mmol) and PdCl₂(PPh₃)₂ (8.6 mg, 0.01 mmol) were added to the mixture simultaneously and the resulting mixture was stirred at room temperature for 1-3 hours. The completion of reaction was monitored by TLC analysis. The reaction was quenched by addition of water and extracted with EtOAc (3 × 10 mL). The combined organic extracts were dried with MgSO₄ and concentrated under reduced pressure. The residue was purified by column chromatography on SiO₂ with hexane/EtOAc (30:1) as an eluent to give a final compound: 14a-g, 17 and 19.

Methyl 2 α -phenylpropynyl-3-oxolup-20(29)-en-28-oate (14a). Colorless crystals (69%). mp 74-76 °C. [α]_D²⁴ 67.6° (c 0.68, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ _H 7.40-7.28 (m, 5H, arom), 4.75, 4.61 (both br s, 2H, H-29), 3.69 (s, 3H, OMe), 3.03 (m, 1H, H-19), 2.94 (m, 1H, H-2), 2.44 (dd, 1H, *J* 15.0, 5.0 Hz, H^a-1), 2.87 and 2.27 (1H each, dd, *J* 15.0, 5.0 Hz, CH₂ in propargyl), 1.69 (s, 3H, H-30), 2.28-1.12 (m, 21H, CH, CH₂ in pentacyclic skeleton and 1H, H^b-1), 1.16, 1.10, 1.08, 1.01, 0.97 (all s, 3H each, H-23–H-27). ¹³C NMR (125 MHz, CDCl₃): δ _C 215.98, 176.61, 150.42, 131.62, 128.18, 127.58, 123.92, 109.73, 88.65, 81.71, 57.32, 56.48, 51.29, 50.14, 49.43, 48.30, 46.98, 46.79, 42.52, 41.76, 40.79, 38.22, 37.47, 36.95, 34.08, 32.15, 30.56, 29.63, 25.43, 25.11, 21.71, 21.19, 20.53, 19.33, 16.13, 14.65. Anal. Calcd for C₄₀H₅₄O₃: C, 82.43; H, 9.34. Found: C, 82.39; H, 9.12 %.

Methyl 2 α -(4-bromophenylpropynyl)-3-oxolup-20(29)en-28-oate (14b). Colorless crystals (71%). mp 88-90 °C. [α]_D²¹ -54.64° (c 0.64, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ _H 7.42 (d, 2H, *J* 8 Hz arom), 7.25 (d, 2H, *J* 8 Hz, arom), 4.75, 4.61 (both br s, 2H, H-29), 3.69 (s, 3H, OMe), 3.03 (m, 1H, H-19), 2.95 (m, 1H, H-2), 2.40 (dd, 1H, *J* 15.0, 5.0 Hz, H^a-1), 2.85 and 2.37 (1H each, dd, *J* 15.0, 5.0 Hz, CH₂ in propargyl), 1.69 (s, 3H, H-30), 2.28-1.12 (m, 21H, CH, CH₂ in pentacyclic skeleton and 1H, H^b-1), 1.15, 1.09, 1.08, 1.00, 0.97 (all s, 3H each, H-23–H-27). ¹³C NMR (100 MHz, CDCl₃): δ _C 215.81, 176.60, 150.45, 133.09, 131.40, 122.87, 121.68, 109.69, 90.00, 80.68, 57.32, 56.48, 51.29, 50.14, 49.42, 48.31, 46.96, 46.83, 42.52, 41.65, 40.79, 38.21, 37.48, 36.93, 34.07, 32.13, 30.56, 29.62, 25.42, 25.08, 21.68, 21.19, 20.56, 19.34, 16.13, 14.64. Anal. Calcd for C₄₀H₅₃BrO₃: C, 72.63; H, 7.98. Found: C, 72.63; H, 7.98 %.

Methyl 2 α -(4-chlorophenylpropynyl)-3-oxolup-20(29)en-28-oate (14c). Colorless crystals (70%). mp 64-66 °C. [α]_D²¹ -52.45° (c 0.57, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ _H 7.32-7.25 (m, 4H, arom), 4.75, 4.61 (both br s, 2H, H-29), 3.69 (s, 3H, OMe), 3.03 (m, 1H, H-19), 2.93 (m, 1H, H-2), 2.44 (dd, 1H, *J* 15.0, 5.0 Hz, H^a-1), 2.85 and 2.37 (1H each, dd, *J* 15.0, 5.0 Hz, CH₂ in propargyl), 1.69 (s, 3H, H-30), 2.27-1.12 (m, 21H, CH, CH₂ in pentacyclic skeleton and 1H, H^b-1), 1.16, 1.09, 1.08, 1.00, 0.97 (all s, 3H each, H(23)–H(27)). ¹³C NMR (100 MHz, CDCl₃): δ _C 215.83, 176.60, 150.45, 133.52, 132.84, 128.47, 122.40, 109.69, 89.77, 80.62, 57.32, 56.48, 51.28, 50.14, 49.42, 48.31, 46.96, 46.84, 42.52, 41.67, 40.79, 38.21, 37.48, 36.93, 34.07, 32.13, 30.56, 29.62, 25.43, 25.08, 21.68, 21.19, 20.53, 19.33, 16.12, 14.63. Anal. Calcd for C₄₀H₅₃ClO₃: C, 77.83; H, 8.65. Found: C, 77.91; H, 8.72 %.

Methyl 2 α -(4-fluorophenylpropynyl)-3-oxolup-20(29)en-28-oate (14d). Colorless crystals (73%). mp 70-73 °C. [α]_D²⁰ -64° (c 1.05, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ _H 7.38-7.28 (m, 2H, arom), 7.01-6.96 (m, 2H, arom), 4.75, 4.61 (both br s, 2H, H-29), 3.69 (s, 3H, OMe), 3.02 (m, 1H, H-19), 2.92 (m, 1H, H-2), 2.40 (m, 1H, H^a-1), 2.85 and 2.37 (1H each, dd, *J* 15.0, 5.0 Hz, CH₂ in propargyl), 1.69 (s, 3H, H-30), 2.27-1.12 (m, 21H, CH, CH₂ in pentacyclic skeleton and 1H, H^b-1), 1.16, 1.09, 1.08, 1.00, 0.97 (all s, 3H each, H(23)–H(27)). ¹³C NMR (100 MHz, CDCl₃): δ _C 215.90, 176.60, 163.67, 161.01, 150.46, 133.43, 133.35, 119.94, 115.48, 115.26, 109.68, 88.27, 80.59, 51.29, 57.32, 56.48, 50.14, 49.41, 48.31, 46.96, 46.83, 42.52, 41.71, 40.79, 38.21, 37.48, 36.93, 34.07,

32.13, 30.56, 29.62, 25.43, 25.08, 21.69, 21.19, 20.46, 19.32, 19.32, 16.12, 16.12, 14.63. Anal. Calcd for $C_{40}H_{53}FO_3$: C, 79.96; H, 8.89. Found: C, 79.89; H, 8.90 %.

Methyl 2 α -(2-methylphenylpropynyl)-3-oxolup-20(29)en-28-oate (14e). Colorless crystals (72%). mp 60-63 °C. $[\alpha]_D^{24} -42.9^\circ$ (c 0.57, $CHCl_3$). 1H NMR (400 MHz, $CDCl_3$): δ_H 7.12-7.38 (m, 4H, arom), 4.75, 4.61 (both br s, 2H, H-29), 3.70 (s, 3H, OMe), 3.02 (m, 1H, H-19), 3.00 (m, 1H, H-2), 2.48 (dd, 1H, J 15.0, 5.0 Hz, H^a -1), 2.42 (s, 3H, Me- C_6H_4), 2.80 and 2.25 (1H each, dd, J 15.0, 5.0 Hz, CH_2 in propargyl), 1.70 (s, 3H, H-30), 2.28-1.12 (m, 21H, CH, CH_2 in pentacyclic skeleton and 1H, H^b -1), 1.17, 1.10, 1.09, 1.01, 0.98 (3H each, all s, H-23-H-27). ^{13}C NMR (100 MHz, $CDCl_3$): δ_C 215.94, 176.63, 150.39, 139.95, 131.79, 129.28, 125.43, 123.69, 121.68, 109.72, 92.69, 80.61, 57.39, 56.50, 51.29, 50.19, 49.42, 48.34, 46.97, 46.80, 42.52, 41.88, 40.79, 38.22, 37.49, 36.95, 34.10, 32.16, 30.57, 29.63, 25.41, 25.05, 21.71, 21.15, 20.85, 20.64, 19.33, 19.33, 16.10, 16.10, 14.63. Anal. Calcd for $C_{41}H_{56}O_3$: C, 82.50; H, 9.46. Found: C, 82.61; H, 9.41 %.

Methyl 2 α -(3,4,5-trimethoxyphenylpropynyl)-3-oxolup-20(29)en-28-oate (14f). Colorless crystals (75%). mp 92-95 °C. $[\alpha]_D^{20} -59.7^\circ$ (c 0.77, $CHCl_3$). 1H NMR (500 MHz, $CDCl_3$): δ_H 6.65 (s, 2H, arom), 4.73, 4.59 (both br s, 2H, H-29), 3.84 (s, 9H, $Ph(OMe)_3$), 3.68 (s, 3H, OMe), 3.01 (m, 1H, H-19), 2.92 (m, 1H, H-2), 2.45 (dd, 1H, J 15.0, 5.0 Hz, H^a -1), 2.80 and 2.39 (1H each, dd, J 15.0, 5.0 Hz, CH_2 in propargyl), 1.68 (s, 3H, H-30), 2.27-1.17 (m, 21H, CH, CH_2 in pentacyclic skeleton and 1H, H^b -1), 1.15, 1.09, 1.07, 1.00, 0.96 (3H each, all s, H-23-H-27). ^{13}C NMR (125 MHz, $CDCl_3$): δ_C 215.92, 176.59, 152.96, 150.50, 138.31, 118.96, 109.66, 108.77, 87.76, 81.86, 51.30, 60.93, 57.27, 56.46, 56.06, 50.13, 49.39, 48.31, 46.97, 46.76, 42.51, 41.60, 40.77, 38.21, 37.42, 36.92, 34.06, 32.11, 30.51, 29.61, 25.44, 25.11, 21.71, 21.22, 20.45, 19.30, 19.30, 16.13, 16.11, 14.62. Anal. Calcd for $C_{43}H_{60}O_6$: C, 76.75; H, 8.99. Found: C, 76.82; H, 9.05 %.

Methyl 2 α -(4-nitrophenylpropynyl)-3-oxolup-20(29)en-28-oate (14g). Colorless crystals (71%). mp 70-72 °C. $[\alpha]_D^{24} -64.4^\circ$ (c 0.65, $CHCl_3$). 1H NMR (500 MHz, $CDCl_3$): δ_H 8.15 (d, 2H, J 8 Hz, arom), 7.52 (d, 2H, J 8 Hz, arom), 4.75, 4.61 (both br s, 2H, H-29), 3.69 (s, 3H, OMe), 3.02 (m, 1H, H-19), 2.97 (m, 1H, H-2), 2.88 and 2.41 (1H each, dd, J 15.0, 5.0 Hz, CH_2 in propargyl), 2.47 (dd, 1H, J 15.0, 5.0 Hz, H^a -1), 1.69 (s, 3H, H-30), 2.28-1.10 (m, 21H, CH, CH_2 in pentacyclic skeleton and 1H, H^b -1), 1.17, 1.10, 1.09, 1.01, 0.97 (all s, 3H each, H(23)-H(27)). ^{13}C NMR (125 MHz, $CDCl_3$): δ_C 215.53, 176.61, 150.51, 146.67, 132.35, 130.94, 123.94, 109.66, 95.02, 80.30, 57.36, 56.48, 51.31, 50.18, 49.40, 48.39, 46.95, 46.95, 42.53, 41.53, 40.80, 38.19, 37.54, 36.93, 34.06, 32.12, 30.55, 29.62, 25.42, 25.04, 21.66, 21.20, 20.72, 19.30, 19.30, 16.17, 16.17, 14.63. Anal. Calcd for $C_{40}H_{53}NO_5$: C, 76.52; H, 8.51. Found: C, 76.48; H, 8.56 %.

Methyl 2 α -phenylpropynyl-3-oxours-12en-28-oate (17). Colorless crystals (75%). mp 78-80 °C. $[\alpha]_D^{19} -40.9^\circ$ (c 0.59, $CHCl_3$). 1H NMR (500 MHz, $CDCl_3$): δ_H 7.41-7.30 (m, 5H, arom), 5.29 (m, 1H, H-12), 3.63 (s, 3H, OMe), 2.96 (m, 1H, H-2), 2.44 (d, 1H, J 15.0 Hz, H^a -1), 2.90 and 2.30 (1H each, dd, J 15.0, 5.0 Hz, CH_2 in propargyl), 2.26 (m, 1H, H-18), 2.06-1.03 (m, 19H, CH, CH_2 in pentacyclic skeleton and 1H, H^b -1), 1.26, 1.12, 1.11, 1.09, 0.84 (all s, 3H each, H-23-H-27), 0.94 (d, J 6 Hz, 3H, H-30), 0.86 (d, J 6 Hz, 3H, H-29). ^{13}C NMR (125 MHz, $CDCl_3$): δ_C 215.91, 178.02, 138.41, 131.60, 128.21, 127.63, 125.20, 123.90, 88.66, 81.78, 57.18, 52.86, 51.48, 48.26, 48.08, 47.06, 46.47, 42.11, 41.72, 39.59, 39.02, 38.86, 37.18, 36.61, 32.71, 30.63, 28.02, 25.36, 24.19, 23.61, 23.52, 22.00, 21.18, 20.54, 19.38, 17.10, 17.10, 15.62. Anal. Calcd for $C_{40}H_{54}O_3$: C, 82.43; H, 9.34. Found: C, 82.50; H, 9.31 %.

Methyl 2 α -phenylpropynyl-3-oxolean-12en-28-oate (19). Colorless crystals (81%). mp 76-79 °C. $[\alpha]_D^{21} -14.52^\circ$ (c 0.79, $CHCl_3$). 1H NMR (400 MHz, $CDCl_3$): δ_H 7.41-7.39 (m, 2H, arom), 7.31-7.29 (m, 3H, arom), 5.32 (m, 1H, H-12), 3.65 (s, 3H, OMe), 2.94 (m, 1H, H-2), 2.87 and 2.43 (1H each, dd, J 15.0, 5.0 Hz, CH_2 of propargyl), 2.36 (d, 1H, J 15.0, 5.0 Hz, H^a -1), 2.01-1.16 (m, 20H, CH, CH_2 in pentacyclic skeleton and 1H, H^b -1), 1.25, 1.14, 1.12, 1.11, 0.82 (all s, 3H each, H-23-H-27), 0.95 (s, 3H, H-29), 0.91 (s, 3H, H-30). ^{13}C NMR (125 MHz, $CDCl_3$): δ_C 215.89, 178.25, 143.97, 131.59, 128.20, 127.61, 123.92, 122.03, 88.62, 81.78, 57.17, 51.55, 48.27, 47.17, 46.72, 46.30, 45.84, 41.76, 41.62, 41.33, 39.38, 37.24, 33.85, 33.11, 32.42, 32.35, 30.69, 27.70, 25.92, 25.33,

23.64, 23.59, 23.05, 21.96, 20.50, 19.37, 17.03, 15.47. Anal. Calcd for $C_{40}H_{54}O_3$: C, 82.43; H, 9.34. Found: C, 82.39; H, 9.27 %.

Synthesis of [3,2-*b*]furan-fused triterpenoids 15a-g, 18a and 20a. Synthesis of [3,2-*b*]furan fused triterpenoids **15a-g**, **18a** and **20a** was carried out as described above for preparation of furans **11a-13a**. The completion of reaction (in 10-12 min) was monitored by TLC analysis.

Methyl 5'-(4-benzylfuran)[3,2-*b*]lup-20(29)-en-28-oate (15a). Colorless crystals (73%). mp 76-79 °C. $[\alpha]_D^{21} +24.0^\circ$ (c 0.66, $CHCl_3$). 1H NMR (400 MHz, $CDCl_3$): δ_H 7.34-7.24 (m, 5H, arom), 5.64 (s, 1H, H-4'), 4.78, 4.64 (both br s, 2H, H-29), 3.94 (s, 2H, CH_2 -5'), 3.70 (s, 3H, OMe), 3.05 (m, 1H, H-19), 2.35 (d, 1H, J 15.0 Hz, H^a -1), 2.28-1.27 (m, 21H, CH, CH_2 in pentacyclic skeleton and 1H, H^b -1), 1.72 (s, 3H, H-30), 1.22, 1.12, 1.01, 0.99, 0.86 (all s, 3H each, H-23-H-27). ^{13}C NMR (125 MHz, $CDCl_3$): δ_C 176.68, 155.11, 152.20, 150.58, 138.74, 128.76, 128.35, 126.22, 113.69, 109.62, 107.59, 56.61, 53.59, 51.28, 49.46, 49.20, 46.98, 42.42, 40.73, 38.60, 38.60, 38.40, 36.97, 34.74, 34.66, 33.50, 32.15, 30.63, 29.13, 29.13, 25.63, 21.39, 21.39, 19.41, 18.97, 16.34, 15.70, 14.71. Anal. Calcd for $C_{40}H_{54}O_3$: C, 82.43; H, 9.34. Found: C, 82.51; H, 9.29. MS (APCI): m/z $[M+H]^+$, found 583. $[C_{40}H_{54}O_3]^+$ requires 582.41.

Methyl 5'-(4-bromobenzyl)furan[3,2-*b*]lup-20(29)-en-28-oate (15b). Colorless crystals (71%). mp 96-98 °C. $[\alpha]_D^{21} +20.49^\circ$ (c 0.37, $CHCl_3$). 1H NMR (400 MHz, $CDCl_3$): δ_H 7.43 (d, 2H, J 5 Hz, arom), 7.12 (d, 2H, J 5 Hz, arom), 5.64 (s, 1H, H-4'), 4.77, 4.63 (both br s, 2H, H-29), 3.93 (s, 2H, CH_2 -5'), 3.70 (s, 3H, OMe), 3.02 (m, 1H, H-19), 2.35 (d, 1H, J 15.0 Hz, H^a -1), 2.27-1.25 (m, 21H, CH, CH_2 in pentacyclic skeleton and 1H, H^b -1), 1.72 (s, 3H, H-30), 1.20, 1.10, 1.00, 0.98, 0.85 (all s, 3H each, H-23-H-27). ^{13}C NMR (100 MHz, $CDCl_3$): δ_C 176.68, 155.40, 151.39, 150.59, 137.75, 131.41, 130.48, 128.75, 113.74, 109.60, 107.82, 56.50, 53.56, 51.28, 49.44, 49.19, 46.97, 42.41, 40.72, 38.59, 38.59, 38.39, 36.96, 34.66, 34.15, 33.14, 32.14, 30.62, 29.78, 29.10, 25.61, 21.36, 21.36, 19.39, 18.95, 16.32, 15.69, 14.69. Anal. Calcd for $C_{40}H_{53}BrO_3$: C, 72.60; H, 8.07. Found: C, 72.54; H, 8.16 %. MS (APCI): m/z $[M+H]^+$, found 661. $[C_{40}H_{53}O_3Br]^+$ requires 660.32.

Methyl 5'-(4-chlorobenzyl)furan[3,2-*b*]lup-20(29)-en-28-oate (15c). Colorless crystals (70%). mp 180-183 °C. $[\alpha]_D^{21} +23.47^\circ$ (c 0.70, $CHCl_3$). 1H NMR (500 MHz, $CDCl_3$): δ_H 7.27 (d, 2H, J 5 Hz, arom), 7.18 (d, 2H, J 5 Hz, arom), 5.64 (s, 1H, H-4'), 4.77, 4.64 (both br s, 2H, H-29), 3.89 (s, 2H, CH_2 -5'), 3.70 (s, 3H, OMe), 3.04 (m, 1H, H-19), 2.36 (d, 1H, J 15.0 Hz, H^a -1), 2.34-1.23 (m, 21H, CH, CH_2 in pentacyclic skeleton and 1H, H^b -1), 1.72 (s, 3H, H-30), 1.21, 1.11, 1.00, 0.99, 0.85 (all s, 3H each, H-23-H-27). ^{13}C NMR (125 MHz, $CDCl_3$): δ_C 176.68, 155.37, 151.52, 150.58, 137.22, 132.02, 130.08, 128.46, 113.74, 109.62, 107.79, 56.50, 53.55, 51.29, 49.44, 49.19, 46.97, 42.41, 40.72, 38.59, 38.56, 38.39, 36.97, 34.66, 34.09, 33.48, 32.14, 30.62, 29.78, 29.10, 25.61, 21.37, 21.37, 19.40, 18.96, 16.33, 15.70, 14.70. Anal. Calcd for $C_{40}H_{53}ClO_3$: C, 77.83; H, 8.65. Found: C, 77.89; H, 8.6 %. MS (APCI): m/z $[M+H]^+$, found 617. $[C_{40}H_{53}O_3Cl]^+$ requires 616.37.

Methyl 5'-(4-fluorobenzyl)furan[3,2-*b*]lup-20(29)-en-28-oate (15d). Colorless crystals (72%). mp 77-79 °C. $[\alpha]_D^{21} +10.3^\circ$ (c 1.97, $CHCl_3$). 1H NMR (500 MHz, $CDCl_3$): δ_H 7.22-7.19 (m, 2H, arom), 7.02-6.97 (m, 2H, arom), 5.63 (s, 1H, H-4'), 4.78, 4.64 (both br s, 2H, H-29), 3.90 (s, 2H, CH_2 -5'), 3.70 (s, 3H, OMe), 3.05 (m, 1H, H-19), 2.35 (d, 1H, J 15.0 Hz, H^a -1), 2.28-1.09 (m, 21H, CH, CH_2 in pentacyclic skeleton and 1H, H^b -1), 1.72 (s, 3H, H-30), 1.23, 1.21, 1.01, 0.99, 0.86 (all s, 3H each, H-23-H-27). ^{13}C NMR (125 MHz, $CDCl_3$): δ_C 176.67, 162.75, 160.32, 155.28, 151.97, 150.58, 134.38, 130.17, 130.09, 115.21, 115.00, 113.71, 109.62, 107.63, 51.27, 56.60, 53.57, 49.45, 49.20, 46.97, 42.41, 40.72, 38.59, 38.59, 38.39, 36.97, 34.66, 33.93, 33.49, 32.14, 30.62, 29.79, 29.10, 25.62, 21.37, 21.37, 19.40, 18.96, 16.33, 15.70, 14.70. Anal. Calcd for $C_{40}H_{53}FO_3$: C, 79.96; H, 8.89 %. Found: C, 79.84; H, 8.82. MS: m/z $[M-H]^+$, found 599.31 $[C_{40}H_{53}O_3F]^+$ requires 600.40.

Methyl 5'-(2-methylbenzyl)furan[3,2-*b*]lup-20(29)-en-28-oate (15e). Colorless crystals (77%). mp 63-65 °C. $[\alpha]_D^{21} +21.76^\circ$ (c 0.60, $CHCl_3$). 1H NMR (500 MHz, $CDCl_3$): δ_H 7.18-7.15 (m, 4H, arom), 5.57 (s, 1H, H-4'), 4.80, 4.66 (both br s, 2H, H-29), 3.92 (s, 2H, CH_2 -5'), 3.72 (s, 3H, OMe), 3.07 (m, 1H, H-19), 2.37 (m, 1H, H^a -1), 2.35 (s, 3H,

Me-C₆H₄), 2.30-1.25 (m, 21H, CH, CH₂ in pentacyclic skeleton and 1H, H^b-1), 1.74 (s, 3H, H-30), 1.25, 1.14, 1.03, 1.01, 0.88 (all s, 3H each, H-23–H-27). ¹³C NMR (125 MHz, CDCl₃): δ_C 176.67, 154.91, 151.76, 150.56, 137.10, 136.43, 130.12, 129.42, 126.50, 125.99, 113.71, 109.67, 107.53, 56.62, 53.59, 51.30, 49.47, 49.21, 46.99, 42.43, 40.74, 38.63, 38.63, 38.41, 36.99, 34.67, 33.53, 32.50, 32.17, 30.65, 29.82, 29.18, 25.65, 21.45, 21.41, 19.49, 19.44, 19.00, 16.38, 15.73, 14.73. Anal. Calcd for C₄₁H₅₆O₃: C, 82.53; H, 9.49. Found: C, 82.49; H, 9.41 %. MS (APCI): *m/z* [M+H]⁺, found 597. [C₄₁H₅₆O₃]⁺ requires 596.42.

Methyl 5'-(3,4,5-trimethoxybenzyl)furano[3,2-*b*]lup-20(29)-en-28-oate (15f). Colorless crystals (73%). mp 83-86 °C. [α]_D²⁰ +18.6° (c 0.85, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ_H 7.47 (s, 2H, arom), 5.71 (s, 1H, H-4'), 4.77, 4.63 (both br s, 2H, H-29), 3.88 (s, 2H, CH₂-5'), 3.84 (s, 9H, Ph(OMe)₃), 3.69 (s, 3H, OMe), 3.04 (m, 1H, H-19), 2.35 (d, 1H, *J* 15 Hz, H^a-1), 2.28-1.24 (m, 21H, CH, CH₂ in pentacyclic skeleton and 1H, H^b-1), 1.71 (s, 3H, H-30), 1.23, 1.12, 1.00, 0.98, 0.86 (all s, 3H each, H-23–H-27). ¹³C NMR (125 MHz, CDCl₃): δ_C 176.66, 155.26, 153.09, 151.79, 150.56, 136.32, 134.57, 113.76, 109.62, 107.78, 105.50, 60.84, 56.59, 55.98, 53.55, 51.28, 49.43, 49.20, 46.96, 42.41, 40.72, 38.61, 38.59, 38.38, 36.96, 34.82, 33.67, 33.48, 32.13, 30.61, 29.78, 29.15, 25.61, 21.40, 21.40, 19.40, 18.97, 16.33, 15.70, 14.70. Anal. Calcd for C₄₃H₆₀O₆: C, 76.56; H, 8.87. Found: C, 76.49; H, 8.85 %. MS: *m/z* [M-H]⁺, found 671.34 [C₄₃H₆₀O₆]⁺ requires 672.44.

Methyl 5'-(4-nitrobenzyl)furano[3,2-*b*]lup-20(29)-en-28-oate (15g). Colorless crystals (19%). mp 60-62 °C. [α]_D²¹ +19.0° (c 0.54, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ_H 8.15 (d, 2H, *J* 5 Hz, arom), 7.39 (d, 2H, *J* 5 Hz, arom), 5.73 (s, 1H, H-4'), 4.77, 4.63 (both br s, 2H, H-29), 4.03 (s, 2H, CH₂-5'), 3.69 (s, 3H, OMe), 3.04 (m, 1H, H-19), 2.36 (d, 1H, *J* 15 Hz, H^a-1), 1.71 (s, 3H, H-30), 2.27-1.25 (m, 21H, CH, CH₂ in pentacyclic skeleton and 1H, H^b-1), 1.19, 1.10, 1.00, 0.98, 0.85 (all s, 3H each, H-23–H-27). ¹³C NMR (100 MHz, CDCl₃): δ_C 176.68, 155.94, 150.59, 149.87, 146.54, 146.54, 129.44, 123.67, 113.92, 109.61, 108.49, 56.59, 53.51, 51.29, 49.42, 49.18, 46.95, 42.41, 40.71, 38.59, 38.50, 38.37, 36.96, 34.68, 34.56, 33.44, 32.12, 30.60, 29.77, 29.07, 25.59, 21.35, 21.35, 19.39, 18.93, 16.32, 15.69, 14.68. Anal. Calcd for C₄₀H₅₃NO₅: C, 76.52; H, 8.51. Found: C, 76.57; H, 8.50 %. MS (APCI): *m/z* [M+H]⁺, found 628. [C₄₀H₅₃NO₅]⁺ requires 627.39.

Methyl 5'-benzylfurano[3,2-*b*]urs-12-en-28-oate (18a). Colorless crystals (71%), mp 76-78 °C. [α]_D¹⁹ +64.8° (c 0.62, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ_H 7.35-7.25 (m, 5H, arom), 5.67 (s, 1H, H-4'), 5.35 (m, 1H, H-12), 3.96 (s, 2H, CH₂-5'), 3.65 (s, 3H, OMe), 2.35 (d, 1H, *J* 15 Hz, H^a-1), 2.30 (m, 1H, H-18), 2.12-1.07 (m, 19H, CH, CH₂ in pentacyclic skeleton and 1H, H^b-1), 1.26, 1.16, 1.14, 0.98, 0.85 (all s, 3H each, H-23–H-27), 0.99 (d, 3H, *J* 5Hz, H-30), 0.93 (d, 3H, *J* 5Hz, H-30). ¹³C NMR (100 MHz, CDCl₃): δ_C 178.06, 155.08, 152.25, 138.75, 138.08, 128.75, 128.37, 126.23, 124.58, 113.64, 107.51, 53.56, 53.07, 51.46, 48.21, 46.13, 42.15, 39.61, 39.17, 38.92, 38.35, 38.35, 36.68, 34.75, 34.57, 32.44, 30.73, 29.34, 28.12, 24.32, 23.52, 23.37, 21.53, 21.21, 19.04, 17.09, 16.82, 15.74. Anal. Calcd for C₄₀H₅₄O₃: C, 82.43; H, 9.34. Found: C, 82.39; H, 9.37 %. MS (APCI): *m/z* [M+H]⁺, found 583. [C₄₀H₅₄O₃]⁺ requires 582.41.

Methyl 5'-benzylfurano[3,2-*b*]olean-12-en-28-oate (20a). Colorless crystals (72%). mp 76-78 °C. [α]_D²⁰ +81.0° (c 0.70, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ_H 7.34-7.31 (m, 5H, arom), 5.66 (s, 1H, H-4'), 5.38 (m, 1H, H-12), 3.95 (s, 2H, CH₂-5'), 3.67 (s, 3H, OMe), 2.93 (m, 1H, H-18), 2.32 (d, 1H, *J* 15 Hz, H^a-1), 2.02-1.22 (m, 19H, CH, CH₂ in pentacyclic skeleton and 1H, H^b-1), 1.25, 1.19, 1.16, 0.96, 0.83 (all s, 3H each, H-23–H-27), 0.98 (s, 3H, H-30), 0.94 (s, 3H, H-30). ¹³C NMR (100 MHz, CDCl₃): δ_C 178.30, 155.12, 152.27, 143.66, 138.74, 128.75, 128.36, 126.23, 122.53, 113.59, 107.51, 53.53, 51.55, 46.82, 46.20, 45.92, 41.82, 41.46, 39.41, 38.40, 38.11, 34.74, 34.56, 33.92, 33.15, 32.41, 32.12, 30.73, 29.31, 27.79, 25.77, 23.71, 23.66, 23.40, 21.54, 19.06, 16.64, 15.56. Anal. Calcd for C₄₀H₅₄O₃: C, 82.43; H, 9.34. Found: C, 82.39; H, 9.28 %. MS (APCI): *m/z* [M+H]⁺, found 583. [C₄₀H₅₄O₃]⁺ requires 582.41.

Halogenolysis of compounds 11a-13a, 15a-f, 18a and 20a with Lil in DMF. Lil (0.85 g, 6.5 mmol) was added to a stirred solution of compound 11a-13a, 15a-f, 18a or 20a (0.4 mmol) in DMF (3 mL). The reaction mixture was

heated under reflux for 5 h (monitoring by TLC), diluted with water (2 mL), and neutralized with 5% HCl (aq). The product was extracted with EtOAc (3×10 mL). The combined extracts were dried with MgSO₄ and concentrated. The residue was purified by column chromatography on SiO₂ with hexane/EtOAc (from 30:1 to 1:10) as an eluent to give compound **11b-13b**, **16a-f**, **18b** and **20b**.

5'-Methylfurano[3,2-*b*]lup-20(29)-en-28-oic acid (11b). Colorless crystals (45%). mp 142-144 °C. $[\alpha]_D^{19} +31.4^\circ$ (c 0.77, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ_H 5.69 (s, 1H, H-4'), 4.79, 4.66 (both br s, 2H, H-29), 3.07 (m, 1H, H-19), 2.37 (d, 1H, *J* 15 Hz, H^a-1), 2.26 (s, 3H, Me-5'), 1.70 (s, 3H, H-30), 2.32-1.27 (m, 21H, CH, CH₂ in pentacyclic skeleton and 1H, H^b-1), 1.22, 1.11, 1.04, 1.02, 0.88 (all s, 3H each, H-23–H-27). ¹³C NMR (125 MHz, CDCl₃): δ_C 183.26, 154.44, 150.38, 149.60, 113.66, 109.76, 106.78, 56.53, 53.60, 49.29, 49.16, 46.96, 42.45, 40.73, 38.64, 38.62, 38.59, 37.07, 34.61, 33.49, 32.16, 30.62, 29.84, 29.17, 25.60, 21.36, 21.36, 19.42, 18.94, 16.31, 15.82, 14.72, 13.73. Anal. Calcd for C₃₃H₄₈O₃: C, 80.44; H, 9.82. Found: C, 80.49; H, 9.86 %. MS (APCI): *m/z* [M–H][–], found 491. [C₃₃H₄₈O₃]⁺ requires 492.36.

5'-Methylfurano[3,2-*b*]urs-12-en-28-oic acid (12b). Colorless crystals (65%). mp 160-163 °C. $[\alpha]_D^{19} +80.4^\circ$ (c 0.92, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ_H 5.69 (s, 1H, H-4'), 5.32 (m, 1H, H-12), 2.35 (d, 1H, *J* 15 Hz, H^a-1), 2.29 (m, 1H, H-18), 2.26 (s, 3H, Me-5'), 2.07-1.05 (m, 19H, CH, CH₂ in pentacyclic skeleton and 1H, H^b-1), 1.22, 1.12, 1.10, 0.96, 0.85 (all s, 3H each, H-23–H-27), 0.97 (d, 3H, *J* 5Hz, H-30), 0.90 (d, 3H, *J* 5Hz, H-30). ¹³C NMR (125 MHz, CDCl₃): δ_C 184.42, 154.42, 149.65, 137.77, 125.99, 113.58, 106.65, 53.55, 52.63, 48.10, 46.12, 42.06, 39.57, 39.11, 38.84, 38.37, 38.30, 36.75, 34.47, 32.39, 30.66, 29.31, 28.05, 24.10, 23.50, 23.34, 21.52, 21.18, 18.93, 16.99, 16.96, 15.66, 13.73. Anal. Calcd for C₃₃H₄₈O₃: C, 80.44; H, 9.82. Found: C, 80.51; H, 9.85 %. MS: *m/z* [M+H]⁺, found 493.07 [C₃₃H₄₈O₃]⁺ requires 492.36.

5'-Methylfurano[3,2-*b*]olean-12-en-28-oic acid (13b). Colorless crystals (48%). mp 138-140 °C. $[\alpha]_D^{19} +84.2^\circ$ (c 0.84, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ_H 5.69 (s, 1H, H-4'), 5.36 (m, 1H, H-12), 2.88 (m, 1H, H-18), 2.31 (d, 1H, *J* 15 Hz, H^a-1), 2.26 (s, 3H, Me-5'), 2.07-1.29 (m, 19H, CH, CH₂ in pentacyclic skeleton and 1H, H^b-1), 1.22, 1.18, 1.11, 0.95, 0.84 (all s, 3H each, H-23–H-27), 0.96 (s, 3H, H-30), 0.93 (s, 3H, H-30). ¹³C NMR (125 MHz, CDCl₃): δ_C 184.58, 154.45, 149.66, 143.42, 122.77, 113.54, 106.65, 53.51, 46.66, 46.22, 45.87, 41.74, 41.03, 39.38, 38.39, 38.09, 34.46, 33.84, 33.08, 32.45, 32.05, 30.69, 29.30, 27.74, 25.78, 23.57, 23.38, 22.95, 21.53, 18.96, 16.86, 15.49, 13.73. Anal. Calcd for C₃₃H₄₈O₃: C, 80.44; H, 9.82. Found: C, 80.50; H, 9.83 %. MS: *m/z* [M+H]⁺, found 493.03 [C₃₃H₄₈O₃]⁺ requires 492.36.

5'-Benzylfurano[3,2-*b*]lup-20(29)-en-28-oic acid (16a). Colorless crystals (45%). mp 252-254 °C. $[\alpha]_D^{19} +28.6^\circ$ (c 0.63, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ_H 7.33-7.22 (m, 5H, arom), 5.63 (s, 1H, H-4'), 4.78, 4.65 (both br s, 2H, H-29), 3.94 (s, 2H, CH₂-5'), 3.05 (m, 1H, H-19), 2.35 (d, 1H, *J* 15.0 Hz, H^a-1), 1.73 (s, 3H, H-30), 2.33-1.27 (m, 21H, CH, CH₂ in pentacyclic skeleton and 1H, H^b-1), 1.22, 1.11, 1.02, 1.01, 0.86 (all s, 3H each, H-23–H-27). ¹³C NMR (125 MHz, CDCl₃): δ_C 182.47, 155.10, 152.23, 150.42, 138.73, 128.76, 128.36, 126.22, 113.67, 109.73, 107.57, 56.48, 53.55, 49.26, 49.12, 46.93, 42.44, 40.72, 38.57, 38.57, 38.57, 37.05, 34.74, 34.66, 33.46, 32.14, 30.59, 29.82, 29.12, 25.58, 21.34, 21.34, 19.40, 18.92, 16.33, 15.81, 14.69. Anal. Calcd for C₃₉H₅₂O₃: C, 82.35; H, 9.21. Found: C, 82.31; H, 9.18 %. MS (APCI): *m/z* [M–H][–], found 567. [C₃₉H₅₂O₃]⁺ requires 568.39.

5'-(4-Brombenzyl)furano[3,2-*b*]lup-20(29)-en-28-oic acid (16b). Colorless crystals (43%). mp 230-232 °C. $[\alpha]_D^{19} +25.68^\circ$ (c 0.26, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ_H 7.43 (d, 2H, *J* 8.0 Hz, arom), 7.12 (d, 2H, *J* 8.0 Hz, arom), 5.64 (s, 1H, H-4'), 4.77, 4.65 (both br s, 2H, H-29), 3.87 (s, 2H, CH₂-5'), 3.05 (m, 1H, H-19), 2.35 (d, 1H, *J* 12.0 Hz, H^a-1), 2.33-1.25 (m, 20H, CH, CH₂ in pentacyclic skeleton), 1.92 (d, 1H, *J* 12.0 Hz, H^b-1), 1.77 (s, 3H, H-30), 1.20, 1.09, 1.01, 1.00, 0.85 (all s, 3H each, H-23–H-27). ¹³C NMR (125 MHz, CDCl₃): δ_C 182.29, 155.38, 151.43, 150.40, 137.74, 131.43, 130.49, 120.08, 113.73, 109.74, 107.80, 56.46, 53.52, 49.25, 49.11, 46.93, 42.44, 40.72, 38.59, 38.56, 38.56, 37.04, 34.66, 34.15, 33.44, 32.13, 30.58, 29.81, 29.10, 25.57, 21.33, 21.33, 19.40, 18.92, 16.33, 15.80, 14.68. Anal. Calcd for C₃₉H₅₁BrO₃: C, 72.32; H, 7.94. Found: C, 72.28; H, 7.96 %.

5'-(4-Chlorobenzyl)furano[3,2-*b*]lup-20(29)-en-28-oic acid (16c). Colorless crystals (45%). mp 263-265 °C. $[\alpha]_D^{19} +25.71^\circ$ (c 0.32, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ_H 7.28 (d, 2H, *J* 8.0 Hz, arom), 7.18 (d, 2H, *J* 8.0 Hz, arom), 5.64 (s, 1H, H-4'), 4.78, 4.64 (both br s, 2H, H-29), 3.89 (s, 2H, CH₂-5'), 3.04 (m, 1H, H-19), 2.35 (d, 1H, *J* 15.0 Hz, H^a-1), 2.30-1.25 (m, 20H, CH, CH₂ in pentacyclic skeleton), 1.91 (d, 1H, *J* 15.0 Hz, H^b-1), 1.77 (s, 3H, H-30), 1.20 1.09, 1.01, 1.00, 0.85 (all s, 3H each, H-23–H-27). ¹³C NMR (125 MHz, CDCl₃): δ_C 182.30, 155.36, 151.55, 150.40, 137.21, 132.02, 130.08, 128.46, 113.72, 109.74, 107.77, 56.46, 53.52, 49.25, 49.12, 46.92, 42.44, 40.72, 38.60, 38.60, 38.56, 37.04, 34.66, 34.09, 33.44, 32.13, 30.58, 29.81, 29.10, 25.57, 21.33, 21.33, 19.40, 18.92, 16.33, 15.80, 14.68. Anal. Calcd for C₃₉H₅₁ClO₃: C, 77.65; H, 8.52. Found: C, 77.69; H, 8.50 %.

5'-(4-Fluorobenzyl)furano[3,2-*b*]lup-20(29)-en-28-oic acid (16d). Colorless crystals (61%). mp 268-2715 °C. $[\alpha]_D^{19} +26.4^\circ$ (c 0.80, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ_H 7.22-7.19 (m, 2H, arom), 7.01-6.98 (m, 2H, arom), 5.63 (s, 1H, H-4'), 4.78, 4.65 (both br s, 2H, H-29), 3.90 (s, 2H, CH₂-5'), 3.05 (m, 1H, H-19), 2.35 (d, 1H, *J* 15.0 Hz, H^a-1), 2.28-1.25 (m, 20H, CH, CH₂ in pentacyclic skeleton), 1.92 (d, 1H, *J* 15.0 Hz, H^b-1), 1.73 (s, 3H, H-30), 1.21 1.10, 1.02, 1.01, 0.86 (all s, 3H each, H-23–H-27). ¹³C NMR (125 MHz, CDCl₃): δ_C 182.54, 162.50, 160.57, 155.26, 152.01, 150.40, 134.34, 130.17, 130.10, 115.19, 115.02, 113.69, 109.74, 107.61, 56.48, 53.53, 49.25, 49.11, 46.93, 42.43, 40.72, 38.60, 38.60, 38.57, 37.06, 34.66, 33.93, 33.45, 32.13, 30.59, 29.82, 29.10, 25.57, 21.33, 21.33, 19.40, 18.91, 16.33, 15.80, 14.68. Anal. Calcd for C₃₉H₅₁FO₃: C, 79.82; H, 8.76. Found: C, 79.92; H, 8.83 %.

5'-(4-Methylbenzyl)furano[3,2-*b*]lup-20(29)-en-28-oic acid (16e). Colorless crystals (45%). mp 260-262 °C. $[\alpha]_D^{19} +21.6^\circ$ (c 0.245, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ_H 7.16-7.13 (m, 4H, arom), 5.55 (s, 1H, H-4'), 4.77, 4.65 (both br s, 2H, H-29), 3.91 (s, 2H, CH₂-5'), 3.05 (m, 1H, H-19), 2.35 (m, 1H, H^a-1), 2.33 (s, 3H, Me-C₆H₄), 2.33-1.25 (m, 20H, CH, CH₂ in pentacyclic skeleton), 1.90 (d, 1H, *J* 15.0 Hz, H^b-1), 1.76 (s, 3H, H-30), 1.22 1.05, 1.01, 1.00, 0.86 (all s, 3H each, H-23–H-27). ¹³C NMR (125 MHz, CDCl₃): δ_C 182.18, 154.90, 151.76, 150.41, 137.09, 136.45, 130.10, 129.41, 126.47, 125.96, 113.68, 109.73, 107.48, 56.46, 53.53, 49.25, 49.11, 46.92, 42.44, 40.72, 38.60, 38.61, 38.56, 37.04, 34.65, 33.47, 32.46, 32.13, 30.59, 29.81, 29.14, 25.58, 21.37, 21.36, 19.45, 19.41, 18.93, 16.33, 15.81, 14.67. ¹³C NMR (see Table 2). Anal. Calcd for C₄₀H₅₄O₃: C, 82.43; H, 9.34. Found: C, 82.51; H, 9.38 %.

5'-(3,4,5-Trimethoxybenzyl)furano[3,2-*b*]lup-20(29)-en-28-oic acid (16f). Colorless crystals (28%). mp 210-212 °C. $[\alpha]_D^{22} +22^\circ$ (c 0.68, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ_H 6.48 (s, 2H, arom), 5.72 (s, 1H, H-4'), 4.78, 4.65 (both br s, 2H, H-29), 3.88 (s, 2H, CH₂-5'), 3.84 (s, 9H, Ph(OMe)₃), 3.06 (m, 1H, H-19), 2.36 (d, 1H, *J* 15 Hz, H^a-1), 2.34-1.28 (m, 20H, CH, CH₂ in pentacyclic skeleton), 2.00 (d, 1H, *J* 15 Hz, H^b-1), 1.73 (s, 3H, H-30), 1.24, 1.12, 1.03, 1.02, 0.87 (all s, 3H each, H-23–H-27). ¹³C NMR (125 MHz, CDCl₃): δ_C 183.07, 155.23, 153.09, 151.83, 150.38, 136.32, 134.58, 113.75, 109.76, 107.77, 105.52, 60.85, 56.51, 55.98, 53.53, 49.26, 49.13, 46.95, 42.44, 40.72, 38.63, 38.59, 38.59, 37.06, 34.83, 33.68, 33.45, 32.14, 30.61, 29.83, 29.15, 25.57, 21.36, 21.36, 19.41, 18.93, 16.33, 15.82, 14.70. Anal. Calcd for C₄₂H₅₈O₆: C, 76.56; H, 8.87. Found: C, 76.47; H, 8.70 %. MS: *m/z* [M-H]⁺, found 657.41 [C₄₂H₅₈O₆]⁺ requires 658.42.

5'-Benzylfurano[3,2-*b*]lup-12-en-28-oic acid (18b). Colorless crystals (55%), mp 126-129 °C. $[\alpha]_D^{19} +64.5^\circ$ (c 0.95, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ_H 7.35-7.24 (m, 5H, arom), 5.67 (s, 1H, H-4'), 5.32 (m, 1H, H-12), 3.96 (s, 2H, CH₂-5'), 2.35 (d, 1H, *J* 15 Hz, H^a-1), 2.25 (d, 1H, *J* 10 Hz, H-18), 2.04 (m, 1H, H^b-1), 2.01-1.07 (m, 19H, CH, CH₂ in pentacyclic skeleton), 1.24, 1.13, 1.12, 0.99, 0.87 (all s, 3H each, H-23–H-27), 0.98 (d, 3H, *J* 5Hz, H-30), 0.91 (d, 3H, *J* 5Hz, H-30). ¹³C NMR (125 MHz, CDCl₃): δ_C 184.54, 155.09, 152.27, 138.76, 137.80, 128.76, 128.37, 126.25, 125.99, 113.61, 107.50, 53.52, 52.62, 48.11, 46.12, 42.06, 39.59, 39.12, 38.85, 38.35, 38.35, 36.76, 34.75, 34.54, 32.38, 30.67, 29.29, 28.07, 24.11, 23.51, 23.33, 21.52, 21.20, 18.94, 17.03, 16.98, 15.72. Anal. Calcd for C₃₉H₅₂O₃: C, 82.35; H, 9.21. Found: C, 82.43; H, 9.27 %. MS: *m/z* [M-H]⁺, found 567.28 [C₃₉H₅₂O₃]⁺ requires 568.391.

5'-Benzylfurano[3,2-*b*]olean-12-en-28-oic acid (20b). Colorless crystals (52%). mp 96-98 °C. $[\alpha]_D^{19} +57.4^\circ$ (c 1.09, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ_H 7.35-7.26 (m, 5H, arom), 5.67 (s, 1H, H-4¹), 5.37 (m, 1H, H-12), 3.96 (s, 2H, CH₂-5¹), 2.90 (m, 1H, H-18), 2.32 (d, 1H, *J* 15 Hz, H^a-1), 2.09 (m, 1H, H^b-1), 2.03-1.25 (m, 18H, CH, CH₂ in pentacyclic skeleton), 1.22, 1.17, 1.14, 1.01, 0.83 (all s, 3H each, H-23–H-27), 0.95 (s, 3H, H-30), 0.94 (s, 3H, H-30). ¹³C NMR (125 MHz, CDCl₃): δ_C 184.82, 155.12, 152.29, 143.44, 138.75, 128.76, 128.38, 126.25, 122.78, 113.58, 107.51, 53.50, 46.67, 46.22, 45.88, 41.74, 41.06, 39.41, 38.43, 38.08, 34.75, 34.55, 33.85, 33.11, 32.45, 32.06, 30.71, 29.29, 27.76, 25.81, 23.60, 23.38, 22.95, 21.53, 18.99, 16.86, 15.56. Anal. Calcd for C₃₉H₅₂O₃: C, 82.35; H, 9.21. Found: C, 82.43; H, 9.27 %. MS: *m/z* [M-H]⁺, found 567.29 [C₃₉H₅₂O₃]⁺ requires 568.39.

Acknowledgements

The authors are deeply thankful to the staff members of the analytical center "Agidel" at the Institute of Petrochemistry and Catalysis of RAS for spectral measurement. This work was performed under financial support from the Russian Foundation for Basic Research (Project No. 16-33-6008).

Supplementary Material

Scans of the PMR and CMR spectra of all new compounds, and tabulated chemical shift data, are presented in the Supplementary file attached to this paper.

References

1. Cichewicz, R. H.; Kouzi, S. A. *Med. Res. Rev.* **2004**, *24*, 90.
<http://dx.doi.org/10.1002/med.10053>
2. Sarek, J.; Kvasnica, M.; Vlk, M.; Urban, M.; Dzubak, P.; Hajduch, M. In *Research on Melanoma: A Glimpse into Current Directions and Future Trends*; Murph, M. Eds.; In Tech: Rijeka, Croatia – European Union, 2011; Vol. 7, p 125.
<http://dx.doi.org/10.5772/19582>
3. Mukherjee, R.; Kumar, V.; Srivastava, S. K.; Agarwal, S. K.; Burman, A. C. *Anti-Cancer Agents Med. Chem.* **2006**, *6*, 271.
<http://dx.doi.org/10.2174/187152006776930846>
4. Ali-Seyed, M.; Jantan, I.; Vijayaraghavan, K.; Bukhari, S. N. A. *Chem. Biol. Drug Des.* **2016**, *87*, 517.
<http://dx.doi.org/10.1111/cbdd.12682>
5. Csuk, R. *Expert Opin. Ther. Pat.* **2014**, *24*, 1.
<http://dx.doi.org/10.1517/13543776.2014.927441>
6. Zhang, D.-M.; Xu, H.-G.; Wang, L.; Li, Y.-J.; Sun, P.-H.; Wu, X.-M.; Wang, G.-J.; Chen, W.-M.; Ye, W.-C. *Med. Res. Rev.* **2015**, *35*, 1127.
<http://dx.doi.org/10.1002/med.21353>
7. Chen, H.; Gao, Y.; Wang, A.; Zhou, X.; Zheng, Y.; Zhou, J. *Eur. J. Med. Chem.* **2015**, *92*, 648.
<http://dx.doi.org/10.1016/j.ejmech.2015.01.031>

8. Lin, C.; Wen, X.; Sun, H. *Expert Opin. Ther. Pat.* **2016**, *26*, 643.
<http://dx.doi.org/10.1080/13543776.2016.1182988>
9. Cui, H. - W.; He, Y.; Wang, J.; Gao, W.; Liu, T.; Qin, M.; Wang, X.; Gao, C.; Wang, Y.; Liu, M.-Y.; Yi, Z.; Qiu, W. *Eur. J. Med. Chem.* **2015**, *95*, 240.
<http://dx.doi.org/10.1016/j.ejmech.2015.03.048>
10. Kvasnica, M.; Urban, M.; Dickinson, N. J.; Sarek, J. *Nat. Prod. Rep.* **2015**, *32*, 1303.
<http://dx.doi.org/10.1039/c5np00015g>
11. Leal, A. S.; Wang, R.; Salvador, J. A. R.; Jing, Y. *Org. Biomol. Chem.* **2013**, *11*, 1726.
<http://dx.doi.org/10.1039/c3ob00011g>
12. Zhang, H.; Zhu, F. Li, P.; Liu, J.; Yao, H.; Jiang, J.; Ye, W.; Wu, X.; Xu, J. *Chem. Biol. Drug Des.* **2015**, *86*, 424.
<http://dx.doi.org/10.1111/cbdd.12543>
13. Borkova, L.; Adamek, R.; Kalina, P.; Drasar, P.; Dzubak, P.; Gurska, S.; Rehulka, J.; Hajduch, M.; Urban, M.; Sarek, J. *Chem. Med. Chem.* **2017**, *12*, 390.
<http://dx.doi.org/10.1002/cmdc.201600626>
14. Xu, J.; Li, Z.; Luo, J.; Yang, F.; Liu, T.; Liu, M.; Qiu, W. -W.; Tang, J. *J. Med. Chem.* **2012**, *55*, 3122.
<http://dx.doi.org/10.1021/jm201540h>
15. Wu, J.; Bao, B.-H.; Shen, Q.; Zhang, Y.-C.; Jiang, Q.; Li, J.-X. *Med. Chem. Commun.* **2016**, *7*, 371.
<http://dx.doi.org/10.1039/c5md00482a>
16. Sousa, M. C.; Varandas, R.; Santos, R.C.; Santos, R. M.; Alves, V.; Salvador, J. A. R. *Plos one* **2014**, *9*, e89939.
<http://dx.doi.org/10.1371/journal.pone.0089939>
17. Laavola, M.; Haavikko, R.; Hämäläinen, R.; Leppänen, T.; Nieminen, R.; Alakurtti, S.; Moreira, V. M.; Yli-Kauhaluoma, J.; Moilanen, E. *J. Nat. Prod.* **2016**, *79*, 274.
<http://dx.doi.org/10.1021/acs.jnatprod.5b00709>
18. Haavikko, R.; Nasereddin, A.; Sacerdoti-Sierra, N.; Kopelyanskiy, D.; Alakurtti, S.; Tikka, M.; Jaffe, Ch. L.; Kauhaluoma, J.Y. *Med. Chem. Commun.* **2014**, *5*, 445.
<http://dx.doi.org/10.1039/c3md00282a>
19. Banerjee, R.; Kumar, HKS.; Banerjee, M. *Int. J. Rev. Life. Sci.* **2012**, *2*, 7.
<https://www.researchgate.net/publication/267423293>
20. Lee, H.-K.; Chan, K.-F.; Hui, C.-W.; Yim, H.-K.; Wu, X.-W.; Wong, H. N. C. *Pure Appl. Chem.* **2005**, *77*, 139.
<http://dx.doi.org/10.1351/pac200577010139>
21. Arcadi, A.; Marinelli, F.; Pini, E.; Rossi, E. *Tetrahedron Lett.* **1996**, *37*, 3387.
<http://dx.doi.org/10.1016/0040-40399600553-9>
22. Vieser, R.; Eberbach, W. *Tetrahedron Lett.* **1995**, *36*, 4405.
<http://dx.doi.org/10.1016/0040-40399500785-B>
23. Vitale, P.; Scilimati, A. *Cur. Org. Chem.* **2013**, *17*, 1986.
<http://dx.doi.org/10.2174/13852728113179990093>
24. Kirsch, S. F. *Org. Biomol. Chem.* **2006**, *4*, 2076.
<http://dx.doi.org/10.1039/b602596j>
25. Belting, V.; Krause, N. *Org. Biomol. Chem.* **2009**, *7*, 1221.
<http://dx.doi.org/10.1039/b819704k>
26. Alonso, F.; Beletskaya, I. P.; Yus, M. *Chem. Rev.* **2004**, *104*, 3079.
<http://dx.doi.org/10.1021/cr0201068>

27. Chang, M.-Y.; Cheng, Y.-C.; Lu, Y.-J. *Org. Lett.* **2015**, *17*, 1264.
<http://dx.doi.org/10.1021/acs.orglett.5b00246>
28. Spivak, A. Yu.; Gubaidullin, R. R.; Galimshina, Z. R.; Nedopekina, D. A.; Odinokov, V. N. *Tetrahedron* **2016**, *72*, 1249.
<http://dx.doi.org/10.1016/j.tet.2016.01.024>
29. Arcadi, A.; Rossi, E. *Tetrahedron* **1998**, *54*, 15253.
<http://dx.doi.org/10.1016/S0040-40209800953-3>
30. Trofimov, B. A.; Schmidt, E. Yu. *Russ. Chem. Rev.* **2014**, *83*, 600.
<https://doi.org/10.1070/RC2014v083n07ABEH004425>
31. Baldwin, J. E. *J. Chem. Soc., Chem. Commun.* **1976**, 734.
<http://dx.doi.org/10.1039/C39760000734>
32. Gilmore, K.; Alabugin, I. V. *Chem. Rev.* **2011**, *111*, 6513.
<http://dx.doi.org/10.1021/cr200164y>
33. Kim, D. S. H. L.; Chen, Z.; Nguyen, T.; Pezzuto, J. M.; Qiu, Sh.; Lu, Z-Z. *Synthetic. Commun.* **1997**, *9*, 1607.
<http://dx.doi.org/10.1080/00397919708006099>